Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia.
10.19540/j.cnki.cjcmm.20200508.501
- Author:
Zhao-Jun LU
1
;
Li-Yin WU
1
;
Yan-Yan MOU
1
;
Han-Min DUAN
1
;
Ru-Cheng CHEN
1
;
Yao XIAO
1
;
Wei-Jun ZHENG
1
Author Information
1. School of Public Health,Zhejiang Chinese Medical University Hangzhou 310053,China.
- Publication Type:Systematic Review
- Keywords:
Lianhua Qingwen;
Meta-analysis;
efficacy;
pneumonia;
safety;
systematic review
- MeSH:
Adult;
Cough;
Drugs, Chinese Herbal/adverse effects*;
Humans;
Pneumonia/drug therapy*;
Treatment Outcome
- From:
China Journal of Chinese Materia Medica
2021;46(4):1000-1009
- CountryChina
- Language:Chinese
-
Abstract:
To systematically evaluate the clinical efficacy and safety of Lianhua Qingwen in the treatment of adult pneumonia. The randomized controlled trial of Lianhua Qingwen combined with conventional Western medicine in the treatment of pneumonia were retrieved from PubMed, EMbase, Wanfang database, VIP database, and CNKI from the establishment of database to March 2020. Two researchers independently conducted literature screening and data extraction, and the third researcher was in charge of arbitration in case of any disagreement. Outcome indicators included total clinical effective rate, symptom improvement time, and incidence of adverse events. R 3.6.1 was used for Meta-analysis, and RevMan 5.3 was used for quality evaluation. Twenty-two studies were included, with a total of 2 007 patients, including 1 017 patients in the experimental group and 990 patients in the control group. The results showed that the total clinical effective rate of the experimental group was higher than that of the control group(RR=1.11, 95%CI[1.08, 1.15], P<0.001), and the antifebrile time(MD=-1.81, 95%CI[-2.42,-1.21], P<0.001), cough duration(MD=-2.32, 95%CI[-2.89,-1.76], P<0.001), rale duration(MD=-2.19, 95%CI[-2.74,-1.63], P<0.001), imaging recovery time(MD=-2.17, 95%CI[-2.76,-1.58], P<0.001) and post-treatment CRP(MD=-4.07, 95%CI[-6.39,-1.75], P<0.001] were all significantly lower than those of the control group. However, it did not proved that the experimental group was safer than the control group(RR=0.84, 95%CI[0.57, 1.24], P=0.382). The results confirmed that Lianhua Qingwen combined with conventional Western medicine in the treatment of pneumonia could improve the clinical treatment efficiency, shorten the time of fever, cough, rale disappearance and imaging recovery, improve CRP index and accelerate the recovery of pneumonia patients. However, the literatures included in this study had a low quality, and the conclusions still need to be further confirmed by more high-quality, multi-center, rigorously designed randomized controlled trial.
